ApoE as a major causative factor and therapeutic target in Alzheimer's disease and other neurodegenerative disorders; small - molecule structure correctors to convert apoE4 to apoE3 and reverse the detrimental effects of apoE4 on mitochondria and the cytoskeleton; small - molecule protease inhibitors to block the formation of toxic fragments of apoE4;
Plasma lipoprotein metabolism regulation involving apoE and apoB;
cholesterol homeostasis modulation by lipoprotein receptors controlling lipoprotein clearance by the liver;
Plasma HDL
cholesterol (HDL - C) metabolism in the progression of atherosclerosis; the genetic epidemiology of the metabolic syndrome and low HDL - C levels established by the Turkish Heart Study.